AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Upgrades AngioDynamics (ANGO) to Outperform
April 5, 2024 7:02 AM EDTOppenheimer analyst Steven M. Lichtman upgraded AngioDynamics (NASDAQ: ANGO) from Perform to Outperform with a price target of $12.00.
The analyst comments "We are upgrading ANGO shares from Perform to Outperform with a $12 PT based on the following: 1) Yesterday's earlier than expected FDA approval... More
AngioDynamics (ANGO) Misses Q3 EPS by 2c
April 4, 2024 7:36 AM EDTAngioDynamics (NASDAQ: ANGO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $66 million versus the consensus estimate of $75.73 million.
GUIDANCE:
AngioDynamics sees FY2024 EPS of ($0.54)-($0.58), versus the consensus of ($0.43). AngioDynamics sees... More
